Last reviewed · How we verify
NCT04037592
Dorsomedial Prefrontal Cortex and the Antidepressant Efficacy of Theta Burst Stimulation in Depressed Patients
NA trial testing Active standardized iTBS-DMPFC in Treatment Resistant Depression in 34 participants. Completed in 31 January 2021.
31 December 2020
Quick facts
| Lead sponsor | Taipei Veterans General Hospital, Taiwan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 24 July 2019 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 January 2021 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Active standardized iTBS-DMPFC
- Active high-dosage iTBS-DMPFC
- Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC
Conditions studied
- Treatment Resistant Depression — all drugs for Treatment Resistant Depression →
Sponsor
Taipei Veterans General Hospital, Taiwan
Who can join
Adults 21 to 70, any sex, with Treatment Resistant Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates an association between different dosage and the antidepressant efficacy of theta burst stimulation in patients with treatment-resistant depression. In a double-blind design, All patients are randomized to three groups, i.e. standardized dosage intermittent theta-burst stimulation treatment, high dosage intermittent theta-burst stimulation treatment or sham treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Antidepressant effects of prolonged intermittent theta-burst stimulation monotherapy at the bilateral dorsomedial prefrontal cortex for medication and standard transcranial magnetic stimulation-resistant major depression: a three arm, randomized, double blind, sham-controlled pil
Cheng CM, Li CT, Jeng JS, Chang WH, et al · · 2023 · cited 6× · PMID 36484844 · DOI 10.1007/s00406-022-01523-4
Verify or expand the search:
- PubMed search for NCT04037592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Treatment Resistant Depression
Currently open trials in the same condition.
- NCT07183748 — Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression · Phase 2 · recruiting
- NCT06938841 — Maintenance rTMS for Depression (Maitr-De) · NA · recruiting
- NCT06236711 — Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD) · NA · active not recruiting
- NCT05774665 — Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression · Phase 2 · active not recruiting
- NCT06895863 — COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression · NA · recruiting
Other Taipei Veterans General Hospital, Taiwan trials
Trials by the same sponsor.
- NCT07463443 — Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Stud · NA · not yet recruiting
- NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
- NCT07362134 — Pulsed-Field Ablation for Recurrent Atypical Atrial Flutter · NA · enrolling by invitation
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07344207 — GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04037592 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Veterans General Hospital, Taiwan
- Last refreshed: 31 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04037592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing